Immix Biopharma, Inc.
Immix Biopharma, Inc.
LOS ANGELES, CA
Loading...
Price History
Market Data
| Market Cap | 23.11M |
| P/E Ratio | - |
| P/B Ratio | 0.25 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | 0.12 |
| Current Ratio | 10.01 |
| Currency | USD |
Key Financial Metrics
-
Revenue
-29.44M
Net Income
-
EPS (Diluted)
-33.61M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-29.96M
Returns & Efficiency
Return on Assets (ROA)
-28.1%
Return on Equity (ROE)
-31.4%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
104.84M
Total Debt
-
Debt to Equity
0.12x
Current Ratio
10.01
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | LOS ANGELES, CA |
| Fiscal Year | 2025 |
Peers
LILLY ELI & CO
LLY
931.26B
P/E: --
ELI LILLY & CO
LLY
931.26B
P/E: --
543.83B
P/E: --
ABBVIE INC.
ABBV
365.53B
P/E: --
BEIGENE, LTD.
BEIGF
306.50B
P/E: 632.4
BEONE MEDICINES LTD.
BEIGF
306.50B
P/E: 632.4
281.00B
P/E: --
MERCK & CO. INC.
MRK
281.00B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$23.11M
P/E Ratio (TTM)-
Price to Book0.25
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-
Net Margin-
ROE-31.4%
ROA-28.1%
Leverage & Liquidity
Debt to Equity0.12
Current Ratio10.01
Total Debt-
Total Assets$104.84M
Stockholders' Equity$93.80M
Income Statement (FY 2025)
Revenue-
Gross Profit-
Operating Income$-29.96M
Net Income$-29.44M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-33.61M
Cash & Equivalents$93.93M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES, CA 90064 |
| Phone | N/A |
| Incorporated | DE, US |
| EIN | 454869378 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 2.42M |
| Stockholders' Equity | $93.80M |
| Cash & Equivalents | $93.93M |
Recent Filings
View All
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-05-04
Local
ARS
Annual Report to Shareholders
Annual report furnished to shareholders
Filed: 2026-04-06
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-06
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2026-04-06
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-30
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-27
Local
S-8
Employee Plan Registration
Registration for employee benefit plan securities
Filed: 2026-03-25
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-25
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-03-25
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-25
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-02-17
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-02-17
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-07
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-08
Local
10-K/A
Amended Annual Report
Amendment to previously filed annual report
Filed: 2025-05-19
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | Immix Biopharma, Inc. |
| Ticker | IMMX |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | LOS ANGELES, CA |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 23.11M |
| Revenue | - |
| Net Income | -29.44M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | - |
| ROE | -31.4% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...